Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.

Authors:
Dari A; Jacqmin P; Iwaki Y; Neyens M; Le Gars M and 4 more

Journal:
CPT Pharmacometrics Syst Pharmacol

Publication Year: 2023

DOI:
10.1002/psp4.13025

PMCID:
PMC10583247

PMID:
37715342

View on PubMed View on PMC View Publisher
Journal Information

Full Title: CPT Pharmacometrics Syst Pharmacol

Abbreviation: CPT Pharmacometrics Syst Pharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediat…
Caleffi-Marchesini ER; Herling AA; Macente J and 8 more (2023) - Transparency Score: 3/6
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progre…
Knöchel J; Bergenholm L; Ibrahim E and 7 more (2023) - Transparency Score: 3/6
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes.
Sokolov V; Yakovleva T; Stolbov L and 4 more (2023) - Transparency Score: 3/6
A "middle-out approach" for the prediction of human drug disposition from preclinical data using si…
Yau E; Gertz M; Ogungbenro K and 2 more (2023) - Transparency Score: 3/6
A model-based approach leveraging in vitro data to support dose selection from the outset: A framew…
Sánchez J; Claus C; Albrecht R and 8 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT A.D., Y.I., M.N., M.L.G., J.S., K.H., J.R.G., and J.J.P.R. are employees of Janssen Research & Development (a Johnson & Johnson company) and may hold stock in Johnson & Johnson. P.J. is a paid consultant of Johnson & Johnson."

Evidence found in paper:

"FUNDING INFORMATION This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025